Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Elston, Marianne S., Love, Amanda, Kevat, Dev, Carroll, Richard, Siow, Zhen Rong, Pattison, Sharon, Boyle, Veronica, Segelov, Eva, Strickland, Andrew H., Wyld, David, Gauci, Richard, Kennedy, Kim, Ransom, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633256/
https://www.ncbi.nlm.nih.gov/pubmed/34697905
http://dx.doi.org/10.1002/cam4.4345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633256/
https://www.ncbi.nlm.nih.gov/pubmed/34697905
http://dx.doi.org/10.1002/cam4.4345

Ejemplares similares